Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Evelio Sosa

Psychiatry Miami, FL Medical Doctor

NPI 1114055761 CMS profile 141523

7171 Sw 24Th St Ste 210, Miami, FL 33155

Open in the dashboard

General payments

$996

13 records reported · program years 2021–2024

Research payments

$1,500

Paid to them · 2 records reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,941,572 paid to institutions, not to them · program years 2021–2025

Through program year 2024, Evelio Sosa of Miami, FL is reported in the CMS Open Payments database as having received $996 across 13 general payments and $1,500 in research payments paid to them. Separately, studies naming them as principal investigator received $6,941,572 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $963 11
2023 Research $600 1
2022 Research $900 1
2021 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evelio Sosa
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Evelio Sosa were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Evelio Sosa Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $34 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $963 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Merck Sharp & Dohme Corporation $939 10 payments
  2. Lundbeck LLC $34 2 payments
  3. Otsuka America Pharmaceutical, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $528 10 payments
  2. Travel and Lodging $469 3 payments
Products named General payments · program years 2021–2024
  1. BRINTELLIX $34 2 payments
  2. REXULTI $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2024
  1. Eli Lilly and Company $1,500 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

9,656

Median for Psychiatry: 574

Drug cost

$55,322

Median for Psychiatry: $27,624

Branded share of claims

10.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Quetiapine Fumarate Generic 1,441 $6,192
Buspirone Hcl Generic 945 $5,756
Clonazepam Generic 745 $4,354
Bupropion Xl Bupropion Hcl Brand 370 $3,764
Trazodone Hcl Generic 1,056 $3,688
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 78 $2,756
Escitalopram Oxalate Generic 741 $2,659
Mirtazapine Generic 417 $2,421
Clozapine Generic 38 $1,778
Venlafaxine Hcl Er Venlafaxine Hcl Brand 200 $1,643

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$12,276

Medicare's payments for the services billed

Medicare patients

88

Average age 81

Services billed

188

65 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 58%
Chronic kidney disease 51%
Ischemic heart disease 49%
Alzheimer's or dementia 48%
Diabetes 42%
COPD 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record